Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

July 12, 2016July 12, 2016

Researchers Say Lung-targeted Gene Therapy May Improve Treatments for Inherited Diseases

Emphysema, News

A team of researchers from the Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center (BMC) developed a new treatment approach using lung-targeted gene therapy, which may ... Read more

July 8, 2016July 8, 2016

Asthma Program With Focused Guidelines Improves Primary Care by 60%

Asthma, News

A recent study showed that a certain set of primary care-based asthma guidelines, established in 2007, helps to improve persistent asthma in children by 60 percent, compared to routine care. The ... Read more

July 7, 2016July 7, 2016

No Link Found Between Fewer Antibiotics Prescriptions and Increase in Bacterial Infections, Researchers Say

News, Pneumonia

According to recent research, reducing the number of prescriptions of antibiotics for respiratory tract infections, such as sore throats, colds, coughs, and ear infections, is not associated with an increase in ... Read more

July 1, 2016July 1, 2016

Cystic Fibrosis Foundation Therapeutics Grants $1.7 Million For Development of New Antimicrobial Drug

Cystic Fibrosis, News

Cystic Fibrosis Foundation Therapeutics (CFFT) based in Maryland, and Alaxia SAS in France, have entered an agreement to help support the first-in-patient clinical trial of ALX-009, an inhaled antimicrobial drug for patients with ... Read more

June 29, 2016June 29, 2016

PH Associated Idiopathic Interstitial Pneumonias: EMA Says ‘No’ to Adempas (Riociguat)

News, Pneumonia, Pulmonary Hypertension

The European Medicines Agency (EMA) has recommended against Adempas (riociguat) for patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP), according to a recent press release. EMA’s recommendation follows Bayer Pharmaceuticals‘ announcement in May for ... Read more

June 28, 2016June 28, 2016

Analysis Shows IPF Treatment OFEV (Nintedanib) Effective in Test, Broader Criteria

Idiopathic Pulmonary Fibrosis, News

The latest analysis of Inpulsis clinical trials demonstrated that Ofev (nintedanib) for idiopathic pulmonary fibrosis slows the disease progression and that treatment results are similar using broader diagnostic criteria than required. The data was ... Read more

June 24, 2016June 24, 2016

Novartis Trial Assesses Ultibro Breezhaler For COPD Flare-Ups

COPD, News

Novartis recently announced encouraging data from a clinical trial evalutating the efficacy of once-daily Ultibro Breezhaler (indacaterol/glycopyrronium bromide) for reducing chronic obstructive pulmonary disease (COPD) flare-ups. The report was published in the New England ... Read more

June 23, 2016June 23, 2016

Positive Data on Lefamulin for CAB Pneumonia Presented by Nabriva

News, Pneumonia

Nabriva Therapeutics AG recently announced new research findings for its lead product candidate lefamulin, the first pleuromutilin antibiotic available for systemic administration in humans. The company is developing both intravenous and ... Read more

June 14, 2016June 14, 2016

New Data on Phase 3 Trial of Quinsair for Cystic Fibrosis Presented by Raptor at European CF Conference

Cystic Fibrosis, News

At the 39th European Cystic Fibrosis Conference, recently held in Basel, Switzerland, Raptor Pharmaceutical presented new data on its Phase 3 MPEX-209 clinical trial comparing Quinsair to inhaled tobramycin solution in patients ... Read more

June 14, 2016June 14, 2016

FDA-Approved Tromethamine May Be Effective in Treating Cystic Fibrosis Airway Disease, Study Shows

Cystic Fibrosis, News

Researchers at the University of Iowa Carver College of Medicine recently reported that the FDA-approved drug tromethamine may offer therapeutic benefits for patients with cystic fibrosis (CF). The findings were described in ... Read more